101 related articles for article (PubMed ID: 19432112)
1. [Prediction of vertebral strength using a CT based finite element method--clinical application in evaluation of the efficacy of alendronate].
Ohnishi I
Nihon Rinsho; 2009 May; 67(5):932-7. PubMed ID: 19432112
[TBL] [Abstract][Full Text] [Related]
2. Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method.
Imai K; Ohnishi I; Matsumoto T; Yamamoto S; Nakamura K
Osteoporos Int; 2009 May; 20(5):801-10. PubMed ID: 18800178
[TBL] [Abstract][Full Text] [Related]
3. Vertebral fracture risk and alendronate effects on osteoporosis assessed by a computed tomography-based nonlinear finite element method.
Imai K
J Bone Miner Metab; 2011 Nov; 29(6):645-51. PubMed ID: 21667358
[TBL] [Abstract][Full Text] [Related]
4. Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial.
Mawatari T; Miura H; Hamai S; Shuto T; Nakashima Y; Okazaki K; Kinukawa N; Sakai S; Hoffmann PF; Iwamoto Y; Keaveny TM
Arthritis Rheum; 2008 Nov; 58(11):3340-9. PubMed ID: 18975334
[TBL] [Abstract][Full Text] [Related]
5. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
Keaveny TM; Donley DW; Hoffmann PF; Mitlak BH; Glass EV; San Martin JA
J Bone Miner Res; 2007 Jan; 22(1):149-57. PubMed ID: 17042738
[TBL] [Abstract][Full Text] [Related]
6. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of bone quality. Effects of osteoporosis medications on structural and mechanical integrity of bone].
Mawatari T; Miura H; Iwamoto Y; Higaki H
Clin Calcium; 2008 Mar; 18(3):354-63. PubMed ID: 18310824
[TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of lumbar vertebral strength in elderly women using computed tomography-based nonlinear finite element model.
Imai K; Ohnishi I; Yamamoto S; Nakamura K
Spine (Phila Pa 1976); 2008 Jan; 33(1):27-32. PubMed ID: 18165745
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the vertebral strength using a finite element model derived from low-dose biplanar imaging: benefits of subject-specific material properties.
Sapin-de Brosses E; Jolivet E; Travert C; Mitton D; Skalli W
Spine (Phila Pa 1976); 2012 Feb; 37(3):E156-62. PubMed ID: 22290213
[TBL] [Abstract][Full Text] [Related]
10. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
11. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
13. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
[TBL] [Abstract][Full Text] [Related]
14. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women.
Sawka AM; Papaioannou A; Adachi JD; Gafni A; Hanley DA; Thabane L
BMC Musculoskelet Disord; 2005 Jul; 6():39. PubMed ID: 16008835
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study.
Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
J Clin Densitom; 2006; 9(2):133-43. PubMed ID: 16785071
[TBL] [Abstract][Full Text] [Related]
16. [Drug therapy for prevention of falls and fractures].
Ringe JD
Med Klin (Munich); 2006 Jun; 101 Suppl 1():1-5. PubMed ID: 16826362
[TBL] [Abstract][Full Text] [Related]
17. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
18. Prediction of vertebral strength under loading conditions occurring in activities of daily living using a computed tomography-based nonlinear finite element method.
Matsumoto T; Ohnishi I; Bessho M; Imai K; Ohashi S; Nakamura K
Spine (Phila Pa 1976); 2009 Jun; 34(14):1464-9. PubMed ID: 19525837
[TBL] [Abstract][Full Text] [Related]
19. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
[TBL] [Abstract][Full Text] [Related]
20. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
